| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2010-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7c87eb8637906d5e3ecffc026476fd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dded2cf11e50cc8f7bd7b1f84e01b10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcbf7121191d502cd88dcb377565ca61 |
| publicationDate |
2010-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010261733-A1 |
| titleOfInvention |
Therapeutic agents 927 |
| abstract |
(2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010173825-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009253676-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7964725-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009105214-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7943607-B2 |
| priorityDate |
2009-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |